Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Bladder Cancer

  Free Subscription


21.10.2019

1 BMC Urol
1 BMJ Open
1 Cancers (Basel)
1 Cell Cycle
1 Curr Mol Pharmacol
1 Eur Urol Oncol
3 Exp Ther Med
1 Expert Rev Mol Diagn
1 Front Pharmacol
1 Genome Med
1 Hum Cell
1 Indian J Urol
1 Int J Mol Sci
1 Int J Urol
1 J Cancer
2 J Cell Physiol
2 J Urol
1 Jpn J Clin Oncol
3 Oncol Lett
1 Orv Hetil
1 PLoS One
2 QJM


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    BMC Urol

  1. WANG TW, Yuan H, Diao WL, Yang R, et al
    Comparison of gemcitabine and anthracycline antibiotics in prevention of superficial bladder cancer recurrence.
    BMC Urol. 2019;19:90.
    PubMed     Text format     Abstract available


    BMJ Open

  2. DE GOEIJ L, Westhoff E, Witjes JA, Aben KK, et al
    The UroLife study: protocol for a Dutch prospective cohort on lifestyle habits in relation to non-muscle-invasive bladder cancer prognosis and health-related quality of life.
    BMJ Open. 2019;9:e030396.
    PubMed     Text format     Abstract available


    Cancers (Basel)

  3. BORKOWSKA EM, Konecki T, Pietrusinski M, Borowiec M, et al
    MicroRNAs Which Can Prognosticate Aggressiveness of Bladder Cancer.
    Cancers (Basel). 2019;11.
    PubMed     Text format     Abstract available


    Cell Cycle

  4. FANG C, Xu L, He W, Dai J, et al
    Long noncoding RNA DLX6-AS1 promotes cell growth and invasiveness in bladder cancer via modulating the miR-223-HSP90B1 axis.
    Cell Cycle. 2019 Oct 15:1-12. doi: 10.1080/15384101.2019.1673633.
    PubMed     Text format     Abstract available


    Curr Mol Pharmacol

  5. BAHRAMI S, Kazemi B, Zali H, Black PC, et al
    Discovering therapeutic protein targets for muscle invasive bladder cancer by proteomic data analysis.
    Curr Mol Pharmacol. 2019 Oct 16. pii: CMP-EPUB-101531.
    PubMed     Text format     Abstract available


    Eur Urol Oncol

  6. VESKIMAE E, Espinos EL, Bruins HM, Yuan Y, et al
    What Is the Prognostic and Clinical Importance of Urothelial and Nonurothelial Histological Variants of Bladder Cancer in Predicting Oncological Outcomes in Patients with Muscle-invasive and Metastatic Bladder Cancer? A European Association of Urology
    Eur Urol Oncol. 2019 Oct 7. pii: S2588-9311(19)30144.
    PubMed     Text format     Abstract available


    Exp Ther Med

  7. WANG B, Wang Z, Zhang T, Yang G, et al
    Overexpression of thymosin beta10 correlates with disease progression and poor prognosis in bladder cancer.
    Exp Ther Med. 2019;18:3759-3766.
    PubMed     Text format     Abstract available

  8. ZHOU K, Yang J, Li X, Chen W, et al
    Long non-coding RNA XIST promotes cell proliferation and migration through targeting miR-133a in bladder cancer.
    Exp Ther Med. 2019;18:3475-3483.
    PubMed     Text format     Abstract available

  9. TANG F, He Z, Lu Z, Wu W, et al
    Application of nomograms in the prediction of overall survival and cancer-specific survival in patients with T1 high-grade bladder cancer.
    Exp Ther Med. 2019;18:3405-3414.
    PubMed     Text format     Abstract available


    Expert Rev Mol Diagn

  10. KOUBA E, Lopez-Beltran A, Montironi R, Massari F, et al
    Liquid biopsy in the clinical management of bladder cancer: current status and future developments.
    Expert Rev Mol Diagn. 2019 Oct 17:1-10. doi: 10.1080/14737159.2019.1680284.
    PubMed     Text format     Abstract available


    Front Pharmacol

  11. ZHU L, Sun J, Wang L, Li Z, et al
    Prognostic and Clinicopathological Significance of PD-L1 in Patients With Bladder Cancer: A Meta-Analysis.
    Front Pharmacol. 2019;10:962.
    PubMed     Text format     Abstract available


    Genome Med

  12. DE JONG JJ, Liu Y, Robertson AG, Seiler R, et al
    Long non-coding RNAs identify a subset of luminal muscle-invasive bladder cancer patients with favorable prognosis.
    Genome Med. 2019;11:60.
    PubMed     Text format     Abstract available


    Hum Cell

  13. LIU S, Chen Q, Wang Y
    MiR-125b-5p suppresses the bladder cancer progression via targeting HK2 and suppressing PI3K/AKT pathway.
    Hum Cell. 2019 Oct 11. pii: 10.1007/s13577-019-00285.
    PubMed     Text format     Abstract available


    Indian J Urol

  14. GRANT CM, Amdur R, Whalen MJ
    Trends in the use of neoadjuvant chemotherapy for bladder cancer with nonurothelial variant histology: An analysis of the National Cancer Database.
    Indian J Urol. 2019;35:291-298.
    PubMed     Text format     Abstract available


    Int J Mol Sci

  15. MARTIN KA, Hum NR, Sebastian A, He W, et al
    Methionine Adenosyltransferase 1a (MAT1A) Enhances Cell Survival During Chemotherapy Treatment and is Associated with Drug Resistance in Bladder Cancer PDX Mice.
    Int J Mol Sci. 2019;20.
    PubMed     Text format     Abstract available


    Int J Urol

  16. FUKUHARA H
    Editorial Comment from Dr Fukuhara to Intraoperative hypotension caused by oral administration of 5-aminolevulinic acid for photodynamic diagnosis in patients with bladder cancer.
    Int J Urol. 2019 Oct 11. doi: 10.1111/iju.14124.
    PubMed     Text format    


    J Cancer

  17. MA W, Ma J, Lei T, Zhao M, et al
    Targeting immunotherapy for bladder cancer by using anti-CD3 x CD155 bispecific antibody.
    J Cancer. 2019;10:5153-5161.
    PubMed     Text format     Abstract available


    J Cell Physiol

  18. YANG Y, Zhang F, Huang H, Xie Z, et al
    Long noncoding RNA LINC00319 regulates ROMO1 expression and promotes bladder cancer progression via miR-4492/ROMO1 axis.
    J Cell Physiol. 2019 Oct 14. doi: 10.1002/jcp.29271.
    PubMed     Text format     Abstract available

  19. WANG F, Cao M, Fan M, Wu H, et al
    AMPK-mTOR-ULK1 axis activation-dependent autophagy promotes hydroxycamptothecin-induced apoptosis in human bladder cancer cells.
    J Cell Physiol. 2019 Oct 16. doi: 10.1002/jcp.29307.
    PubMed     Text format     Abstract available


    J Urol

  20. RITCH CR, Velasquez MC, Kwon D, Becerra MF, et al
    Utility and Validation of the AUA/SUO Risk Grouping for Non-muscle Invasive Bladder Cancer in a Contemporary Cohort.
    J Urol. 2019 Oct 14:101097JU0000000000000593. doi: 10.1097/JU.0000000000000593.
    PubMed     Text format     Abstract available

  21. CHANG SS
    Re: Occupation and Bladder Cancer Phenotype: Identification of Workplace Patterns That Increase the Risk of Advanced Disease beyond Overall Incidence.
    J Urol. 2019 Oct 16:101097JU0000000000000599. doi: 10.1097/JU.0000000000000599.
    PubMed     Text format    


    Jpn J Clin Oncol

  22. NITTA M, Kuroda S, Nagao K, Higure T, et al
    Effect of neoadjuvant chemotherapy in patients undergoing radical cystectomy for muscle-invasive bladder cancer: a retrospective, multi-institutional study.
    Jpn J Clin Oncol. 2019 Oct 15. pii: 5587304. doi: 10.1093.
    PubMed     Text format     Abstract available


    Oncol Lett

  23. YOSHIDA T, Sopko NA, Kates M, Liu X, et al
    Impact of spheroid culture on molecular and functional characteristics of bladder cancer cell lines.
    Oncol Lett. 2019;18:4923-4929.
    PubMed     Text format     Abstract available

  24. DING ZS, He YH, Deng YS, Peng PX, et al
    MicroRNA-34a inhibits bladder cancer cell migration and invasion, and upregulates PTEN expression.
    Oncol Lett. 2019;18:5549-5554.
    PubMed     Text format     Abstract available

  25. YUAN S, Luan X, Han G, Guo K, et al
    LINC01638 lncRNA mediates the postoperative distant recurrence of bladder cancer by upregulating ROCK2.
    Oncol Lett. 2019;18:5392-5398.
    PubMed     Text format     Abstract available


    Orv Hetil

  26. SZARVAS T, Olah C, Riesz P, Geczi L, et al
    [Molecular subtype classification of urothelial bladder cancer and its clinical relevance].
    Orv Hetil. 2019;160:1647-1654.
    PubMed     Text format     Abstract available


    PLoS One

  27. FANG CW, Hsieh VC, Huang SK, Tsai IJ, et al
    A population-based cohort study examining the association of documented bladder diverticulum and bladder cancer risk in urology patients.
    PLoS One. 2019;14:e0222875.
    PubMed     Text format     Abstract available


    QJM

  28. CHEREMISIN D, Andropova P, Gavrilov P
    Reply to: BCG infection following immunotherapy for bladder cancer.
    QJM. 2019 Oct 14. pii: 5586893. doi: 10.1093.
    PubMed     Text format    

  29. MOSINA N, Kayukov I
    Renal tuberculosis following BCG therapy for bladder cancer.
    QJM. 2019 Oct 14. pii: 5586891. doi: 10.1093.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Bladder Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: